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Radiolabeled pro-urokinase plasminogen activator (pro-uPA) was cross-linked to a specific protein on the surface of human monocyte-like U937 
cells in a reaction catalyzed by tissue transglutaminase. The conjugate formed with this unknown component had a much higher molecular weight 
(apparent A4, 250,00@-300,000) than the complex of pro-uPA and the urokinase plasminogen activator receptor (uPAR). There was a strong 
preference for the pro-form of uPA. The conjugate was recognized by antibodies against uPA but not by anti-uPAR antibodies. Nevertheless, the 
blocking of uPAR with a monoclonal antibody abolished the formation of the conjugate, thus showing a role of uPAR in this process. 
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1. INTRODUCTION 
The urokinase plasminogen activator (uPA) is a 
serine protease which plays a trigger role in the prote- 
olytic cascade of plasminogen activation. This cascade 
system has critical functions in degradation processes in 
the extracellular matrix which occur under a number of 
normal as well as pathological conditions, including 
cancer invasion [1,2]. UPA is synthesized and secreted 
in the form of a proenzyme (pro-uPA) which is activated 
by plasmin or certain other proteases [2] into the active 
two-chain enzyme. 
utilized tissue transglutaminase, an abundant enzyme 
capable of introducing a covalent cross-link between 
certain proteins [12-141. 
2. MATERIALS AND METHODS 
2.1. Proteins 
A number of cell types possess a specific UPA recep- 
tor (uPAR) [3-51, a glycoplipid-anchored cell surface 
protein which has been thoroughly characterized [6-81 
and which plays a critical role in the localization and 
regulation of plasminogen activation. Thus, in some cell 
types receptor-binding confines UPA to cell-cell and 
focal cell-substratum contact sites [9,10], and the con- 
comitant binding of pro-uPA to uPAR and of plasmin- 
ogen to unknown components on the cell leads to a 
strong enhancement of plasmin generation [l 11. These 
and other processes dependent on receptor binding of 
UPA are assumed to involve interactions with other, as 
yet unidentified cell surface molecules [l 11. In order to 
study such interactions we have in the present work 
The following reagents were purchased from the sources indicated: 
tissue transglutaminase from guinea pig liver (Sigma, Saint Louis, 
MO), active (two-chain) human uPA (Serono, Aubonne, Switzerland) 
and laminin from mouse EHS sarcoma (Boehringer-Mannheim, Ger- 
many). Purified, recombinant human pro-uPA was a kind gift from 
Dr. P. Sarmientos, Farmitalia Carlo Erba, Milan, Italy. Diisopro- 
pyhluorophosphate-(DFP)-treated two-chain uPA was prepared as 
described [15]. The monoclonal and polyclonal antibodies used have 
been described previously [16-181. Proteins were labeled with ‘25I as 
published [6], except that an incubation period of only 10 min was 
used. 
2.2. Ligand binding and cross-linking with transglutaminase 
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Abbreviations: u-PA, urokinase-type plasminogen activator; pro-uPA, 
single-chain proenzyme form of uPA; u-PAR, u-PA receptor; 
DFP, diisopropylfluorophosphate; PBS, phosphate-buffered saline; 
CHAPS, 3-[(3cholamidopropyl)dimethylammonio]-l-propanesulfon- 
ate; DSS, N,K-disuccinimidyl-suberate; SDS-PAGE, sodium dodccyl 
sulfate polyacrylamide gel electrophoresis. 
Human histiocytic lymphoma cells of the U937 line were grown as 
described [4] and were seeded in fresh medium the day before the 
experiment. Immediately before the assay, the cells were washed in 50 
mM HEPES, 100 mM NaCl, 5 mM CaCl,, pH 7.4 (binding buffer) and 
resuspended in binding buffer with 0.1% BSA at a density of 5 x lo6 
cells per ml. Each sample was made up of 200@ of this cell suspension. 
The cells were preincubated in the presence or absence of various 
competitor proteins as indicated, for 15 min at 4°C on a shaking table. 
‘2SI-labeled pro-uPA (or other labeled ligands, as specified) was then 
added to the samples at approx. 1.5 nM final concentration. The 
samples were incubated as above at 4°C for 1 h, after which the 
volume was made up to 1 ml with binding buffer. The cells were 
collected by centrifugation, and 800@ of the supematant was removed 
and discarded. The cells were resuspended in the remaining 200 ~1 of 
buffer, after which tissue transglutaminase (final concentration 
20 pg/ml) was added to the samples. Control samples received no 
enzyme. The cells were transferred to 37°C and incubated for 30 min, 
after which the reaction was stopped by the addition of 800 ~1 of 
phosphate-buffered saline with 10 mM EDTA (PBS-EDTA). The cells 
were washed twice in PBS-EDTA and recovered in a volume of 
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100 ~1. The samples were then placed on ice, and the cells were lysed 
by the addition of CHAPS (1% final concentration). The lysates were 
clarified by centrifugation at 20,000 x g for 10 min at 4°C. All cell 
lysates were analyzed by SDS-PAGE followed by autoradiography. 
2.3. Other methods 
Chemical cross-linking with N,N-disuccinimidylsuberate (DSS) 
and termination of this reaction with ammonium acetate were per- 
formed as described [15], except hat the samples were handled in the 
buffers specified above for transglutaminase-catalyzed cross-linking. 
SDS-PAGE was performed according to [19] and was done under 
non-reducing conditions unless otherwise stated, on a 616% gradient 
slab gel. 
3. RESULTS 
3.1. Tissue transglutaminase cross-links a specific, cell 
surface pro-uPA complex 
U937 cells were incubated with ‘251-labeled pro-uPA, 
followed by tissue transglutaminase, in a Ca2+-contain- 
ing buffer. Clarified detergent lysates of the cells were 
analyzed by SDS-PAGE and autoradiography (Fig. 
1A). 
The presence of transglutaminase l d to the forma- 
tion of an SDS-resistant, radiolabeled conjugate which 
migrated with an apparent M, of 25&300,000 (lane 2; 
see also Fig. 2), irrespective of whether reducing (result 
not shown) or non-reducing sample treatment was used 
before electrophoresis. The reaction was strikingly spe- 
cific; this sharp protein band was the only labeled prod- 
uct of the transglutaminase treatment (compare lanes 2 
and 3 of Fig. 1A). 
When labeled, active uPA or labeled, DFP-inac- 
tivated two-chain uPA was used as the ligand instead of 
pro-uPA, the transglutaminase failed to form the conju- 
gate (Fig. lB, lane 2; result shown for labeled DFP- 
UPA). 
In a variant of the assay, we subjected the cells to acid 
treatment for removal of endogenous, receptor-bound 
UPA [ 151 and used unlabeled instead of labeled ligands 
for incubation, followed by detection by Western blot- 
ting (results not shown). After incubation of the cells 
with 120 nM of pro-uPA followed by 50 pg/ml of tissue 
transglutaminase, the M, 250-300,000 conjugate was 
detected as a strong band, using monoclonal anti-uPA 
antibodies (clones 5 and 6 [16,17]) or polyclonal anti- 
bodies against UPA [17]. However, a very weak band 
was also detected at the conjugate position in samples 
incubated with active uPA or DFP-treated two-chain 
UPA in the same, high concentration, indicating that the 
prefernce for the pro-form of uPA was not absolute. 
3.2. The transglutaminase-catalyzed cross-linking is de- 
pendent on the binding of pro-uPA to the uPA recep- 
tor 
The present conjugate was clearly different from the 
complex formed with the previously characterized 
uPAR of M, 55,000 [6] which could be demonstrated in 
the same samples by chemical cross-linking with DSS, 
using radiolabeled ligands (Fig. 1A and B, lane 1; la- 
beled conjugate of apparent il4, 90,000). 
Nevertheless, we found that preincubation of the cells 
with the monoclonal anti-uPAR antibody, R3, which 
has previously been shown to inhibit uPA-binding to 
uPAR [18], completely prevented the formation of the 
conjugate, whereas there was no effect of the antibodies 
R2 and R4, which bind to uPAR without preventing 
ligand binding [18] (Fig. 2). Preincubation with an ex- 
cess of unlabeled UPA (Fig. 2) or pro-uPA (result not 
shown), both of which are known to block uPAR [4], 
also efficiently prevented the transglutaminase cross- 
linking reaction. However, while pointing to a role of 
uPAR in complex formation, these tidings do not im- 
plicate that uPAR itself is part of the covalent adduct. 
In Western blotting experiments, performed as above, 
the M, 250-300,000 conjugate failed to react with mono- 
clonal (clones R2, R3 or R4 [18]) or polyclonal anti- 
uPAR antibodies, even under conditions where a clear 
reaction was found with the unconjugated uPAR. Fur- 
thermore, using tissue transglutaminase, we have been 
unable to cross-link pro-uPA to purified, recombinant 
uPAR [20], or to polymerize pro-uPA:uPAR complexes 
(results not shown). 
4. DISCUSSION 
The present work demonstrates a novel pro-uPA 
complex on the surface of U937 cells. The complex was 
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Fig. 1. Tissue transglutaminase incorporates pro-uPA into a specific, 
high molecular weight complex on U937 cells. Cells were incubated 
with ‘zsI-labeled pro-uPA (Panel A) or DFP-uPA (Panel B), followed 
by either of the following treatments: chemical cross-linking with DSS 
(lane 1), incubation with tissue transglutaminase (lane 2) or incubation 
with buffer alone (lane 3). Detergent cell lysates were analyzed by 
SDS-PAGE and autoradiography. The M, of molecular weight 
marker proteins are indicated; the top of the figure aligns with the 
upper edge of the separation gel. In this gel system with non-reduced 
samples, the unconjugated ligands migrate with an apparent M, of 
42,000 (pro-uPA) and 46,000 (DFP-uPA), respectively. 
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Fig. 2. Formation of the complex is dependent on uPAR. Binding of 
radiolabeled pro-uPA to U937 cells followed by incubation with 
transglutaminase were performed as in Fig. 1 A, lane 2, except that the 
cells had been pre-incubated with the following monoclonal antibodies 
or other reagents: buffer (lane 1), anti-trinitrophenol (irrelevant anti- 
body control; 20 &ml) (lane 2), anti-uPAR R3 (20 &ml) (lane 3), 
anti-uPAR R2 (20 &ml) (lane 4), anti uPAR R4 (20 @ml) (lane S), 
or uPA (100 nM) (lane 6). The molecular weight marker proteins 
include a sample of reduced and alkylated laminin (A-chain: M, 
400,000; B, and B, chains: A4, 220,000 [14]). 
found after transglutaminase-catalyzed cross-linking, 
but the detection of just a single binding product, as well 
as the requirement for an unblocked uPAR, makes it 
clear that the complex formation was the result of spe- 
cific recognition events and/or steric arrangements of 
the reactants. Transglutaminase-catalyzed fixation of 
non-covalent protein complexes is a well established 
phenomenon [12]. In the present reaction, there was a 
strong preference for the pro-form of UPA. 
The demonstration of a new, uPAR-dependent, pro- 
UPA binding product is of considerable interest, because 
the glycolipid-anchored uPAR:ligand complex is in- 
volved in several processes which appear to require 
interactions with other cell surface molecules. These 
processes include the potentiation of the plasminogen 
activation cascade and the directioning of surface- 
bound pro-uPA to contact sites, discussed above, and 
also internalization of uPA:inhibitor complexes [21-231 
and a proposed role of uPAR in cellular signal 
transduction [24]. 
It is a relevant possibility that, also in vivo, covalent 
fixation of the present complex may occur in addition to 
the non-covalent interactions that form the background 
for the specificity. Tissue transglutaminase and closely 
related transglutaminases are widespread in the organ- 
ism, e.g. occurring in erythrocytes, endothelial cells and 
hepatocytes [12]. In the latter cell type, tissue transglu- 
taminase participates in covalent reactions on the ex- 
tracellular surface [13], and the enzyme has also been 
shown to bind to extracellular matrix components [25]. 
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